The Founder
“Who writes the check?”
Has built and sold companies. Thinks in unit economics, positioning, and whether a business can survive contact with the market. Names the buyer and what budget the check comes from. Stress-tests what happens when the underlying model gets 10x cheaper or a platform player ships 80% of this for free.
Gets excited about
- +Pricing aligned with value delivered
- +Products where the AI is the margin, not the cost
- +Natural expansion revenue built into the product
Tired of
- -"We'll figure out monetization later"
- -TAM slides that count everyone with an internet connection
- -Wrapper businesses with no defensibility
Healthcare verdicts(1 tools, 0 shipped)
Open-weight vision model fine-tuned for radiology and clinical imaging
“The buyer here is a clinical researcher or academic institution, which means the check comes from a grant budget or a research IT line — small, slow, and heavily committee-gated. Meta isn't building a business with this release; they're publishing a research artifact, so the 'pricing is free' observation misses the point — the real question is what Meta captures, and the answer is talent signaling and ecosystem influence, not revenue. The moat for anyone trying to commercialize on top of this is essentially nonexistent: the weights are public, the fine-tune recipe will be replicated, and the research license strips out the highest-value commercial use cases. If I were a founder building on this, I'd need a very specific workflow integration — structured report templating, PACS system connectors, audit logging — to create switching costs, because the model itself is not the business.”
Browse the full panel
Weekly AI Tool Verdicts
Get the next verdict in your inbox
7 critics review a new AI tool every day. Weekly digest — free.